Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions

Scandinavian Journal of Immunology

Volumn 61, Issue 3, 2005, Pages 251-259

  Wells, J W ^a   Darling, D ^a   Farzaneh, F ^a   Galea Lauri, J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; OVALBUMIN;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CELL FUNCTION; CELL POPULATION; CELL STIMULATION; CYTOKINE RELEASE; DENDRITIC CELL; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PHENOTYPE; PINOCYTOSIS; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD11C; BONE MARROW CELLS; CULTURE MEDIA, SERUM-FREE; DENDRITIC CELLS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-4; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; PHENOTYPE;

EID: 16244375551     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01556.x     Document Type: Article

References (34)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. Sallusto F, Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res 2002;4 (Suppl. 3):S127-32.
3. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997;9:10-16.
4. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-9.
5. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
6. Lutz MB, Kukutsch N, Ogilvie AL et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999;223:77-92.
7. Son YI, Egawa S, Tatsumi T, Redlinger RE Jr, Kalinski P, Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods 2002;262:145-57.
8. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998;95:9482-7.
9. Lee WC, Wang HC, Jeng LB et al. Effective treatment of small murine hepatocellular carcinoma by dendritic cells. Hepatology 2001;34:896-905.
10. Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarisation and efficacy of anti-tumour T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 2004;53:963-77.
11. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
12. Dillon SM, Hart DN, Abernethy N, Watson JD, Baird MA. Priming to mycobacterial antigen in vivo using antigen-pulsed antigen presenting cells generated in vitro is influenced by the dose and presence of IL-4 in APC cultures. Scand J Immunol 1997;46:1-9.
13. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999;48:2300-8.
14. Lu L, McCaslin D, Srarzl TE, Thomson AW. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 1995;60:1539-45.
15. Labeur MS, Roters B, Pers B et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168-75.
16. Lutz MB, Suri RM, Niimi M et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30:1813-22.
17. Masurier C, Pioche-Durieu C, Colombo BM et al. Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: implications for anti-tumoral cell therapy. Immunology 1999;96:569-77.
18. Morel PA, Vasquez AC, Feili-Hariri M. Immunobiology of DC in NOD mice. J Leukoc Biol 1999;66;276-80.
19. Eggert AO, Becker JC, Ammon M et al. Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 2002;32:122-7.
20. Toldbod HE, Agger R, Bolund L, Hokland M. Potent influence of bovine serum proteins in experimental dendritic cell-based vaccination protocols. Scand J Immunol 2003;58:43-50.
21. Buchele S, Hopfl R. Presentation of tetanus toxoid to autologous T cells by dendritic cells generated from human blood. Improved specificity with dendritic cells generated without fetal calf serum. Adv Exp Med Biol 1997;417:233-7.
22. Jonuleit H, Giesecke A, Kandemir A, Paragnik L, Knop J, Enk AH. Induction of tumor peptide-specific cytotoxic T cells under serum-free conditions by mature human dendritic cells. Arch Dermatol Res 2000;292:325-32.
23. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-42.
24. Tarte K, Fiol G, Rossi JF, Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia 2000;14:2182-92.
25. Muller G, Muller A, Jonuleit H et al. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches. J Invest Dermatol 2000;114:142-9.
26. Barnden MJ, Allison J, Hearh WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha-and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998;76:34-40.
27. Robertson JM, Jensen PE, Evavold BD. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 2000;164:4706-12.
28. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
29. Miller G, Lahrs S, Dematteo RP. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB J 2003;17:728-30.
30. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
31. Ebner S, Ratzinger G, Krosbacher B et al. Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4. J Immunol 2001;166:633-41.
32. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999;162:3231-6.
33. Feili-Hariri M, Morel PA. Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin Immunol 2001;98:133-42.
34. Lutz MB, Schnare M, Menges M et al. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002;169:3574-80.